M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma

M2-polarized macrophages promote metastatic behavior of Lewis lung carcinoma cells by inducing vascular endothelial growth factor-C expression

(2012) B Zhang et al.   Clinics

Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab

(2011) J. Pander et al.   CLINICAL CANCER RESEARCH

M2-Polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma

(2011) Bicheng Zhang et al.   Clinics

Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer

(2011) Fu-Tsai Chung et al.   INTERNATIONAL JOURNAL OF CANCER

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

(2011) William D. Travis et al.   Journal of Thoracic Oncology

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma

(2010) Yoichi Ohtaki et al.   Journal of Thoracic Oncology

Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma

(2010) Bi Cheng Zhang et al.   MEDICAL ONCOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL)

(2010) Daisuke Niino et al.   PATHOLOGY INTERNATIONAL

Tumor-Associated Macrophage Correlated with Angiogenesis and Progression of Mucoepidermoid Carcinoma of Salivary Glands

(2009) Yi-Shing Shieh et al.   ANNALS OF SURGICAL ONCOLOGY

Mutations and Response to Epidermal Growth Factor Receptor Inhibitors

(2009) P. Laurent-Puig et al.   CLINICAL CANCER RESEARCH

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2009) W. Wang et al.   CLINICAL CANCER RESEARCH

Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma

(2009) Bicheng Zhang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

(2009) Akira Inoue et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

(2009) T John et al.   ONCOGENE

Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors

(2009) Kyoko Kawamura et al.   PATHOLOGY INTERNATIONAL

Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas

(2008) C.-H. Lee et al.   CLINICAL CANCER RESEARCH

Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas

(2008) Y Komohara et al.   JOURNAL OF PATHOLOGY

Macrophage activation and polarization

(2007) Fernando Oneissi Martinez   Frontiers in Bioscience-Landmark